公开(公告)号：EP4437814A1

公开(公告)日：2024-10-02

申请号：EP22821946.5

申请日：2022-11-23

Applicant: Merck Patent GmbH

Inventor： STOESSEL, Philipp

IPC: H10K85/60 ,  C07C13/00

CPC classification number: H10K85/6572 ,  H10K85/342 ,  H10K50/165 ,  H10K50/18 ,  H10K50/11 ,  H10K2101/9020230201 ,  H10K85/615 ,  C07C255/52 ,  C07D307/91 ,  C07D235/20 ,  C07D209/86 ,  C07D251/14 ,  C07D405/04 ,  C07D239/26 ,  C07D333/76 ,  C07D403/04 ,  C07D327/08 ,  C07D491/048 ,  C07D487/06 ,  C07D405/14 ,  C07D495/04 ,  C07D471/04 ,  C07D487/04 ,  C07D209/80 ,  C07D495/14 ,  C07C2603/9020170501

公开(公告)号：EP3374343A1

公开(公告)日：2018-09-19

申请号：EP16804960.9

申请日：2016-11-09

Applicant: Battelle Memorial Institute

Inventor： LALGUDI, Ramanathan S. ,  CAFMEYER, Jeffrey T. ,  CAIN, Robert J. ,  GARBARK, Daniel B.

IPC: C07C51/41 ,  C07C67/38 ,  C07C67/03 ,  C07D235/20 ,  C08G63/08 ,  C08G63/16 ,  C08G73/10 ,  C07C69/34

CPC classification number: C07D235/20 ,  C07C51/412 ,  C07C67/03 ,  C07C67/38 ,  C08G63/16 ,  C08G69/26 ,  C07C55/02 ,  C07C69/34

Abstract: Linear α, ω-nonadecanediester derivatives and methods of making the derivatives are described. The methods include reacting a linear α, ω-nonadecanediester or a linear α, ω-nonadecanedicarboxylic acid with a reactant optionally in the presence of at least one of a solvent and a catalyst to form the α, ω-nonadecanediester derivative. Methods of making linear α, ω-nonadecanediester or diester derivatives are also described.

公开(公告)号：EP2669275B1

公开(公告)日：2016-11-16

申请号：EP12740009.1

申请日：2012-01-26

Applicant: National University Corporation Shizuoka University

Inventor： KONDO, Mitsuru

IPC: C07D235/20 ,  B01J41/08 ,  B01J47/12 ,  C02F1/42 ,  C07F1/08 ,  C07F15/04

CPC classification number: C07D235/20 ,  B01J41/09 ,  B01J47/018 ,  C02F1/42 ,  C02F2001/422 ,  C07F1/005

公开(公告)号：EP2307520B1

公开(公告)日：2015-11-11

申请号：EP09776787.5

申请日：2009-06-19

Applicant: Merck Patent GmbH

Inventor： STOESSEL, Philipp ,  HEIL, Holger ,  JOOSTEN, Dominik ,  PFLUMM, Christof ,  GERHARD, Anja ,  BUESING, Arne ,  KAISER, Joachim

IPC: C09K11/06 ,  H01L51/50 ,  C07D235/20 ,  C07D251/24 ,  C07D251/28 ,  C07D519/00 ,  C07D209/86

CPC classification number: H01L51/005 ,  C07C1/2076 ,  C07C15/16 ,  C07C45/61 ,  C07C49/786 ,  C07C49/792 ,  C07C221/00 ,  C07C225/22 ,  C07C2603/97 ,  C07D209/86 ,  C07D213/50 ,  C07D235/20 ,  C07D251/24 ,  C07D251/28 ,  C07D519/00 ,  C09B1/00 ,  C09B57/00 ,  C09B57/008 ,  C09K11/025 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1014 ,  C09K2211/185 ,  H01L51/0056 ,  H01L51/0058 ,  H01L51/0059 ,  H01L51/006 ,  H01L51/0067 ,  H01L51/0072 ,  H01L51/0081 ,  H01L51/0085 ,  H01L51/5012 ,  H01L51/5048 ,  H01L51/5056 ,  H01L51/5072 ,  H01L51/5088 ,  H01L51/5096 ,  Y02E10/549

公开(公告)号：EP2809656A2

公开(公告)日：2014-12-10

申请号：EP12814106.6

申请日：2012-12-27

Applicant: ALLERGAN, INC. ,  Ehring, George, R. ,  Adorante, Joseph, S. ,  Garst, Michael E. ,  Rind, Howard, B. ,  Hansen, Mark, R. ,  Avey, Jr., Alfred, A. ,  Dolby, Lloyd, J. ,  Esfandiari, Shervin ,  Mackenzie, Vivian, R. ,  Marsden, Jeremiah, A. ,  Muchmore, David, C.

Inventor： EHRING, George, R. ,  ADORANTE, Joseph, S. ,  GARST, Michael, E. ,  RIND, Howard, B. ,  HANSEN, Mark, R. ,  AVEY, JR., Alfred, A. ,  DOLBY, Lloyd, J. ,  ESFANDIARI, Shervin ,  MACKENZIE, Vivian, R. ,  MARSDEN, Jeremiah, A. ,  MUCHMORE, David, C.

IPC: C07D235/06 ,  C07D235/08 ,  C07D235/12 ,  C07D235/20 ,  C07D401/12 ,  C07D403/06 ,  A61P25/00 ,  A61P25/08 ,  A61P27/02 ,  A61P29/00 ,  A61K31/4184

CPC classification number: C07D235/12 ,  C07D235/06 ,  C07D235/08 ,  C07D235/14 ,  C07D235/20 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12

Abstract: The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein R, R
1 , R
2 , R
3 , R
4 , m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.

公开(公告)号：EP2766354A1

公开(公告)日：2014-08-20

申请号：EP12783247.5

申请日：2012-10-09

Applicant: Orion Corporation

Inventor： LINNANEN, Tero ,  WOHLFAHRT, Gerd ,  NANDURI, Srinivas ,  UJJINAMATADA, Ravi ,  RAJAGOPALAN, Srinivasan ,  MUKHERJEE, Subhendu

IPC: C07D401/14 ,  C07D403/04 ,  C07D413/04 ,  A61K31/4184 ,  A61K31/4188 ,  A61P35/00 ,  C07D471/04

CPC classification number: A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  C07D235/20 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: A compound of formula (I), wherein R
3 , R
4 , G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Abstract translation: 公开了其中R 3，R 4，G，B，M和Z如权利要求中所定义的式（I）化合物及其药学上可接受的盐。 式（I）化合物具有作为FGFR抑制剂的用途，并且可用于治疗需要FGFR激酶抑制的病症，例如癌症。

公开(公告)号：EP2749560A1

公开(公告)日：2014-07-02

申请号：EP13775204.4

申请日：2013-04-12

Applicant: LG Chem, Ltd.

Inventor： LEE, Dong Hoon ,  PARK, Tae Yoon ,  HONG, Sung Kil ,  JANG, Boonjae ,  CHUN, Minseung ,  KIM, Dong Sik ,  KANG, Minyoung

IPC: C07D403/12 ,  C07D403/10 ,  C09K11/06 ,  H01L51/50

CPC classification number: H01L51/0072 ,  C07D235/02 ,  C07D235/20 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C09B57/00 ,  C09K11/06 ,  C09K2211/1011 ,  C09K2211/1029 ,  C09K2211/1044 ,  H01L51/0052 ,  H01L51/0058 ,  H01L51/006 ,  H01L51/0067 ,  H01L51/0068 ,  H01L51/0073 ,  H01L51/0074 ,  H01L51/0077 ,  H01L51/5012 ,  H01L51/5056 ,  H01L51/5072 ,  H01L51/5088 ,  H01L51/5092 ,  Y02E10/549

Abstract: The present application provides a new nitrogen-containing heterocyclic compound and an organic electronic device using the same.

公开(公告)号：EP2698367A1

公开(公告)日：2014-02-19

申请号：EP12180482.7

申请日：2012-08-14

Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

Inventor： Waldmann, Herbert ,  Triola, Gemma ,  Wittinghofer, Alfred ,  Shehab, Ismail ,  Bastiaens, Philippe ,  Vartak, Nachiket ,  Papke, Björn ,  Zimmermann, Gunther

IPC: C07D235/08 ,  C07D235/12 ,  C07D235/14 ,  C07D235/18 ,  C07D235/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D487/04 ,  C07D493/10 ,  A61K31/404 ,  A61P35/00

CPC classification number: C07D235/08 ,  C07D235/12 ,  C07D235/14 ,  C07D235/18 ,  C07D235/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D487/04 ,  C07D493/10

Abstract: The present invention relates to novel substituted benzimidazoles and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted benzimidazoles together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted benzimidazoles binding to the prenyl binding pocket of PDEδ have been identified as useful for the prophylaxis and treatment of cancer by the inhibition of the binding of PDEδ to K-Ras and of oncogenic Ras signalling in cells by altering its localization leading to cell death or inhibition of proliferation.

Abstract translation: 本发明涉及这些化合物的新型取代的苯并咪唑和立体异构形式，前体药物，溶剂合物，水合物和/或药学上可接受的盐，以及含有这些取代的苯并咪唑中的至少一种以及药学上可接受的载体，赋形剂和/或稀释剂 。 已经鉴定了与PDE'的异戊烯基结合口袋结合的所述新型取代的苯并咪唑可用于通过改变其局部化引导而抑制PDE与K-Ras的结合和癌细胞中的致癌性Ras信号传导来预防和治疗癌症 到细胞死亡或抑制增殖。

公开(公告)号：EP1690855B1

公开(公告)日：2014-01-22

申请号：EP06111503.6

申请日：2001-11-21

Applicant: Symrise AG

Inventor： BERTRAM, Ralf ,  HILLERS, Stephan ,  KOCH, Oskar ,  ERFURT, Harry ,  REINDERS, Gerald

IPC: A61Q17/04 ,  C07D235/20 ,  C07D235/18 ,  A61K8/49

CPC classification number: A61K8/49 ,  A61K8/4946 ,  A61Q17/04 ,  C07D235/20

公开(公告)号：EP2279185B1

公开(公告)日：2014-01-15

申请号：EP09721867.1

申请日：2009-03-19

Applicant: LEK Pharmaceuticals d.d.

Inventor： CASAR, Zdenko ,  COPAR, Anton ,  CLUZEAU, Jerome ,  PREMRL, Andrej

IPC: C07D403/04

CPC classification number: C07C17/263 ,  C07C17/14 ,  C07C17/2632 ,  C07D235/20 ,  Y10T436/147777 ,  C07C25/18